Clinical trial NCT01813838: GFM-Acadesine: A Phase I-II Trial of Acadesine
Official title: A Phase I-II Trial of Acadesine in IPSS High and Int-2 SMD, LAM With 20-30% Marrow Blasts and CMML Type 2 Not Responding to Azacitidine or Decitabine for at Least 6 Courses or Relapsing After a Response
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: SMD
Lead sponsor: Groupe Francophone des Myelodysplasies
Sponsor class: OTHER
Collaborators: name: Advancell - Advanced In Vitro Cell Technologies, S.A.
First posted: 2013-03-19
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A phase I-II trial of Acadesine in IPSS high and int 2 myelodysplastic syndromes, acute myeloid leukemia with 20-30% marrow blasts and chronic myelomonocytic leukemia type 2 not responding to Azacitidine or Decitabine for at least 6 courses or relapsing after a response:

Patients will receive 6 treatment cycles unless disease progression, transformation, or unacceptable toxicity occurs, or the patient refuses to continue participating in the study.

Efficacy will be assessed at the end of the 2nd, 4th and 6th cycles. After 6 cycles, patients demonstrating a response (CR, PR, marrow CR, or HI) will be able to continue with cycles of Acadesine (at the same dose as in the preceding cycles, depending on their cohort) until progression.

Detailed description: Primary objectives

Phase I:

To determine the maximal tolerated dose (MTD) and dose limiting toxicities (DLTs) of increasing doses of IV Acadesine administered on D1, D3, D5, D8, D10 and D12 of 28 to 56 day-courses

Phase II:

To confirm safety and hematological toxicity in 18 additional patients

Secondary objectives:

Phase I:

* To determine response rates, as defined by the 2006 modified IWG criteria,
* To evaluate response duration, time to IPSS progression, and loss of RBC transfusion independence in these patients.
* To evaluate hospitalization duration, rates of rehospitalization for non-hematological toxicities, severe bleeding or febrile neutropenia.

Phase II:

To determine

* response rate as defined by the 2006 modified IWG criteria
* toxicity profile and safety
* response duration
* rate of progression to AML
* overall survival

Eligibility criteria: Inclusion Criteria:

* Myelodysplastic syndrome including the following WHO categories: refractory anemia with excess blasts (RAEB), non-proliferative chronic myelomonocytic leukemia (CMML) (leukocytes \< 13 G/L but \> 10% marrow blasts), WHO- AML with 20-30% marrow blasts (RAEB-T according to the FAB classification)
* Prior treatment with Azacitidine or Decitabine for at least 6 courses without response (including CR, PR, marrow CR and stable disease with hematological improvement) or relapse after a response
* IPSS score \>1 (IPSS: Int-2 or High);
* Age ≥ 18 years;
* Normal liver function tests, defined by total bilirubin and transaminases less than 1.5 time the upper limit of normal;
* Normal renal function, defined by creatinine less than 1.5 time the upper limit of normal, creatinine clearance ≥ 50 mL/min.
* Patient ineligible for allogeneic hematopoietic stem cell transplantation;
* Written informed consent;
* Patient must understand and voluntarily sign consent form;
* Patient must be able to adhere to the visit schedule as outlined in the study and follow protocol requirements;
* ECOG performance status between 0-2 at the time of screening;
* Women of childbearing potential must:

Agree to use effective contraception without interruption throughout the study and for a further 1 month after the end of treatment;

* Men must:

Agree to not conceive during the treatment and to use effective contraception during the treatment period (including periods of dose reduction or temporary suspension) and for a further 1 month after the end of treatment if their partner is of childbearing potential.

Exclusion Criteria:

* Severe infection or any other uncontrolled severe condition
* Significant cardiac disease - NYHA Class III or IV or having suffered a myocardial infarction in the last 6 months
* Less than 30 days since prior treatment with growth factors (EPO, G-CSF)
* Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of hydroxyurea. The patient must have recovered from all acute toxicities from any previous therapy.
* Active cancer, or cancer during the year prior to trial entry other than basal cell carcinoma or carcinoma in situ of the cervix or breast;
* Patient already enrolled in another therapeutic trial of an investigational drug;
* HIV infection or active hepatitis B or C;
* Women who are or could become pregnant or who are currently breastfeeding;
* Any medical or psychiatric contraindication that would prevent the patient from understanding and signing the informed consent form;
* Patient eligible for allotransplantation.
* Known allergy to acadesine or any of its excipients
* No affiliation to an insurance system

Primary outcomes:
measure: Determine the maximal tolerated dose (MTD)
timeFrame: 6 month of treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Bayonne
country: France
facility: Centre hospitalier de la côte Basque
city: Bobigny
country: France
facility: Hôpital Avicenne
city: Bordeaux Pessac
country: France
facility: CHU de Haut-Lévèque
city: Creteil
country: France
facility: Centre henri Mondor
city: Grenoble
country: France
facility: CHU de Grenoble
city: Limoges
country: France
facility: CHU de Limoges
city: Marseille
country: France
facility: Institut paoli calmettes
city: Meaux
country: France
facility: centre hospitalier de Meaux
city: Nantes
country: France
facility: CHU de nantes
city: Nice
country: France
facility: Centre Antoine Lacassagne
city: Nice
country: France
facility: Hôpital L'archet 1, Nice
city: Paris
country: France
facility: Hôpital Saint Louis
city: Paris
country: France
facility: Hôpital Saint Antoine
city: Paris
country: France
facility: Hôpital Saint-Louis
city: Paris
country: France
facility: Hôpital Cochin
city: Rouen
country: France
facility: Centre henri Becquerel
city: Tours
country: France
facility: Hôpital Bretonneau de Tours
Study officials:
affiliation: Hôpital Saint Louis, Paris, France
name: Thomas Cluzeau, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hôpital Saint Louis, Paris, France
name: Pierre Fenaux, MD
role: PRINCIPAL_INVESTIGATOR
References: